

13 June 2026



To,

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE Scrip Code: 543308
ISIN: INE967H01025

National Stock Exchange of India Limited
The Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra – Kurla Complex, Bandra (East)
Mumbai – 400 051
NSE Symbol: KIMS
ISIN: INE967H01025

Dear Madam/ Sir,

Subject: Outcome of the meeting of the Board of Directors of Krishna Institute of Medical Sciences Limited (the “Company”) held today i.e., Saturday, 13 June 2026 in terms of the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”).

Further to the prior intimation made on 10 June 2026 under Regulation 29(1)(d) of the SEBI LODR Regulations and pursuant to Regulation 30 read with Schedule III of the SEBI LODR Regulations read along with the SEBI Master Circular bearing reference number SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026 (“**SEBI Disclosure Circular**”), we wish to inform you that the Board of Directors of the Company (“**Board**”) in its meeting held today, i.e., Saturday, 13 June 2026 has *inter-alia* considered and approved the following:

1. **Issue of warrants fully convertible into equity shares of ₹ 2/- each on a preferential basis to members of the promoter and promoter group of the Company (as identified in the table below) by way of preferential allotment on a private placement basis (“Preferential Allotment”):**

Subject to approval of the shareholders of the Company and of such other regulatory/governmental authorities, as may be required, the Board has approved to create, offer, issue and allot by way of a preferential allotment on a private placement basis, an aggregate of 77,02,182 (Seventy-Seven Lakh Two Thousand One Hundred And Eighty-Two) warrants, each fully convertible into, or exchangeable for 1 (one) fully paid-up equity share of the Company of face value ₹ 2/- (Rupees Two only) each, at a price of ₹ 779.00 (Indian Rupees Seven Hundred and Seventy-Nine only) (including a premium of ₹ 777.00 each (Indian Rupees Seven Hundred and Seventy-Seven only)) (“**Warrant Issue Price**”) being not less than the higher of the floor price determined in accordance with the provisions of Regulation 164 of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“**SEBI ICDR Regulations**”) and the provisions of the articles of association of the Company, i.e., basis the price determined by the valuation report of a registered valuer, each payable in cash (“**Warrants**”), which may be exercised in one or more tranches during the period commencing from the date of allotment of the Warrants until expiry of 18 (Eighteen) months, to the following persons (along with the number of Warrants proposed to be allotted to each such person) as set out in the table below, for cash consideration aggregating to ₹ 599,99,99,778/- (Five Hundred Ninety-Nine Crore Ninety-Nine Lakh Ninety-Nine Thousand Seven Hundred And Seventy-Eight Only)/- in accordance with the provisions of the Companies Act, 2013, the rules made thereunder and SEBI ICDR Regulations.

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

Table A. Details of proposed allottee:

Sr. No.	Name of Proposed allottee and details	Category	Number of Warrants proposed to be allotted	Aggregate Consideration Receivable (₹)
1.	Dr. Abhinay Bollineni	Promoter	32,09,242	₹ 2,49,99,99,518/-
2.	Mr. Adwik Bollineni	Promoter	32,09,242	₹ 2,49,99,99,518/-
3.	Bharas Ventures LLP, a limited liability partnership with Dr. Bhaskara Rao Bollineni (being Promoter of the Company) and Ms. Rajyasri Bollineni (being Promoter of the Company) having made the entire capital contribution of Bharas Ventures LLP	Promoter Group	12,83,698	₹ 1,00,00,00,742/-
	Total		77,02,182	₹ 5,99,99,99,778/-

The Relevant Date for the purpose of issue of Warrants on preferential basis in accordance with Chapter V of SEBI ICDR Regulations is Tuesday, 09 June 2026.

The details with respect to the issuance of securities as required pursuant to Regulation 30 of the SEBI LODR Regulations read along with the SEBI Disclosure Circular is set out below at **Annexure – A**.

2. Approval of issue of notice for Extra-Ordinary General Meeting:

The Board has approved the convening of an Extra-Ordinary General Meeting (“EGM”) of the shareholders of the Company on 09 July 2026, through video conferencing or other audio-visual means, for seeking necessary approval of the members of the Company for the aforesaid matters. The Board approved the draft of the EGM notice and other related matters. The notice for the said EGM shall be submitted to the stock exchanges in due course in compliance with applicable provisions of the SEBI LODR Regulations.

The necessary details of the extraordinary general meeting including the notice thereof shall be intimated to the stock exchanges separately in due course.

The meeting commenced at 10:30 AM and concluded at 12:45 PM

A copy of this disclosure is being uploaded on the website of the Company at <https://www.kimshospitals.com/investors/>

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Krishna Institute of Medical Sciences Limited,

Nagajayanthi J. R.
Company Secretary & Compliance Officer

ANNEXURE A

Disclosure pursuant to Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular bearing reference number SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30 January 2026

Sr. No.	Particulars	Details				
1	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Warrants, each convertible or exchangeable into 1 (one) fully paid-up equity share of the Company of face value of ₹2/- (Rupees Two only) each, i.e., 1 equity share for 1 warrant.				
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential allotment of Warrants on a private placement basis in accordance with Chapter V of the SEBI ICDR Regulations and other applicable laws.				
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	77,02,182 (Seventy-Seven Lakh Two Thousand One Hundred And Eighty-Two) Warrants, convertible or exchangeable, within 18 (Eighteen) months of allotment of the Warrants, into equivalent number of fully paid-up equity shares having face value of ₹ 2/- (Indian Rupees Two only), each at a price of ₹ 779.00/- (Indian Rupees Seven Hundred And Seventy Nine only) (including a premium of ₹ 777.00/- each (Indian Rupees Seven Hundred and Seventy-Seven only)) per Warrant aggregating to ₹ 599,99,99,778/- (Indian Rupees Five Hundred Ninety-Nine Crore Ninety-Nine Lakh Ninety-Nine Thousand Seven Hundred And Seventy-Eight only).				
4	In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s):					
4.1	Names of the investors	1. Dr. Abhinay Bollineni (Promoter) 2. Mr. Adwik Bollineni (Promoter) 3. Bharas Ventures LLP (Promoter Group)				
4.2	Post allotment of securities - outcome of the subscription					
		Name of the Proposed Allottees	Pre-Preferential Issue shareholding (no. of Shares)	Pre-Preferential Issue shareholding (%)	Post-Preferential Issue shareholding (no. of Shares) (assuming 100% conversion of warrants)	Post-Preferential Issue shareholding (%) (assuming 100% conversion of warrants)
		Dr. Abhinay Bollineni	2,36,495	0.06%	34,45,737	0.84%
		Mr. Adwik Bollineni	40,640	0.01%	32,49,882	0.80%
		Bharas Ventures LLP, a	NIL	NIL	12,83,698	0.31%

		limited liability partnership, with Dr. Bhaskara Rao Bollineni (being Promoter of the Company) and Ms. Rajyasri Bollineni (being Promoter of the Company) having made the entire capital contribution of Bharas Ventures LLP				
			Pre-Preferential Issue shareholding (no. of Shares) *	Pre-Preferential Issue shareholding (%)*	Post-Preferential Issue shareholding (no. of Shares) (assuming 100% conversion of warrants)	Post-Preferential Issue shareholding (%) (assuming 100% conversion of warrants)
		Promoter and Promoter Group	13,64,89,330	34.11%	14,41,91,512	35.35%
		<p><i>* Given the Proposed Allotees form part of the promoter and promoter group of the Company, we have disclosed the shareholding for the promoter and promoter group of the Company, as publicly available, basis the quarterly shareholding pattern for the quarter ended 31 March 2026.</i></p>				
4.3	Issue price / allotted price (in case of convertibles)	<p>₹ 779.00/- (Indian Rupees Seven Hundred And Seventy Nine only) (including a premium of ₹ 777.00/- each (Indian Rupees Seven Hundred and Seventy-Seven only)) per Warrant (i.e., Warrant Issue Price), being not less than the higher of the floor price determined as per the provisions of Regulation 164 of Chapter V of the SEBI ICDR Regulations and the provisions of the articles of association of the Company, i.e., basis the price determined by the valuation report of a registered valuer.</p>				

		The Relevant Date for the purpose of determining the Warrant Issue Price in accordance with Chapter V of SEBI ICDR Regulations is Tuesday, 09 June 2026.
4.4	Number of investors	Three (3) All form part of the promoter and promoter group of the Company.
4.5	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Each Warrant will be convertible into, or exchangeable for, 1 (one) fully paid-up equity share of the Company of face value of ₹2/- (Indian Rupees Two only), which may be exercised in one or more tranches during a period of 18 (eighteen) months commencing from the date of allotment of the Warrants. An amount equivalent to 25% of the Warrant Issue Price shall be payable at the time of subscription and allotment of the Warrants and the holder of the Warrants will be required to make the balance payment of 75% of the Warrant Issue Price at the time of exercise of the right attached to the Warrants to convert the Warrants and subscribe to the equity shares of the Company. The tenure of the Warrants shall not exceed 18 (eighteen) months from the date of allotment of the Warrants. If the entitlement against the Warrants to apply for the equity shares of the Company is not exercised by the Warrant holder within the aforesaid period of 18 (eighteen) months, the entitlement of the Warrant holder to apply for equity shares of the Company along with the rights attached thereto shall expire and any amount paid by the Warrant holder on such Warrants shall stand forfeited by the Company.
5	Nature of Consideration	Cash
6	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable